Hori­zon low­ers ex­pec­ta­tions for Te­pez­za and ad­justs its strat­e­gy for the year ahead

One of Hori­zon Ther­a­peu­tics’ top sell­ers isn’t per­form­ing as well as ex­pect­ed, CEO Tim Wal­bert re­vealed on Wednes­day’s Q2 call, lead­ing the phar­ma com­pa­ny to switch up its strat­e­gy.

While Wal­bert not­ed a 13% in­crease in sales last quar­ter, to­tal­ing $876.4 mil­lion, the chief ex­ec­u­tive low­ered his full-year ex­pec­ta­tions for the thy­roid eye dis­ease (TED) drug Te­pez­za. While the drug was ini­tial­ly ex­pect­ed to see a per­cent­age growth in the mid-30s, Wal­bert now an­tic­i­pates a sales growth in the high-teens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER